- Home
- RILYP vs GALT Comparison
RILYP vs GALT Comparison
Compare RILYP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RILYP | GALT |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | United States |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RILYP | GALT |
|---|---|---|
| Price | $3.60 | $6.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 38.1K | ★ 465.8K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $854,383,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.73 | $0.73 |
| 52 Week High | $20.00 | $6.66 |
Technical Indicators
Market Signals| Indicator | RILYP | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 59.79 |
| Support Level | $3.74 | $5.10 |
| Resistance Level | $3.97 | $6.32 |
| Average True Range (ATR) | 0.28 | 0.54 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 23.77 | 82.05 |
Price Performance
Historical ComparisonAbout RILYP B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.